4 completed, 1 active not recruiting, 1 withdrawn. 4 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow naptumomab estafenatox: new trials by email Literature Review of naptumomab estafenatox trials Research Report on naptumomab estafenatox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab - Urothelial Carcinoma | Phase 1 | Withdrawn | Weill Medical College of Cornell University | 2023-11-01 | 2024-04-12 | |
| NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab - Non-small Cell Lung Cancer | Phase 2 | Completed | NeoTX Therapeutics Ltd. | 38 | 2021-10-26 | 2025-03-03 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab - ER+ Breast Cancer, Ovarian Cancer | Phase 1 | Active not recruiting | NeoTX Therapeutics Ltd. | 120 | 2019-10-10 | 2025-11-28 |
| ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma ABR-217620/naptumomab estafenatox, IFN-alpha - Renal Cell Carcinoma | Phase 2 / Phase 3 | Completed | Active Biotech AB | 526 | 2007-01-01 | 2015-07-22 |
| ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer ABR-217620, docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | Active Biotech AB | 13 | 2005-11-01 | 2014-08-27 |
| ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer ABR-217620 - Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma | Phase 1 | Completed | Active Biotech AB | 44 | 2003-04-01 | 2014-08-27 |
Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Melanoma (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Active Biotech AB (3) · NeoTX Therapeutics Ltd. (2) · Weill Medical College of Cornell University (1)
United States (4) · Russia (2) · United Kingdom (2) · Bulgaria (1) · Denmark (1) · India (1) · Israel (1) · Norway (1) · Romania (1) · Ukraine (1)
Suzanne Kilany (2) · Cora Sternberg, M.D. (1) · Ilana Lorber, MD (1) · Tal Hetzroni Kedem (1) · Thore Nederman, PhD (1)